Evoke Pharma Current Ratio 2012-2018 | EVOK

Evoke Pharma current ratio from 2012 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Evoke Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.01B $0.00B 4.35
2018-06-30 $0.01B $0.00B 5.23
2018-03-31 $0.01B $0.00B 4.67
2017-12-31 $0.01B $0.00B 3.82
2017-09-30 $0.01B $0.00B 4.06
2017-06-30 $0.01B $0.00B 7.00
2017-03-31 $0.02B $0.00B 13.05
2016-12-31 $0.01B $0.00B 6.58
2016-09-30 $0.01B $0.00B 10.69
2016-06-30 $0.01B $0.01B 0.75
2016-03-31 $0.01B $0.00B 2.82
2015-12-31 $0.01B $0.00B 5.19
2015-09-30 $0.01B $0.00B 5.82
2015-06-30 $0.01B $0.00B 3.32
2015-03-31 $0.01B $0.00B 5.03
2014-12-31 $0.02B $0.00B 8.24
2014-09-30 $0.01B $0.00B 7.90
2014-06-30 $0.02B $0.00B 9.22
2014-03-31 $0.02B $0.00B 7.48
2013-12-31 $0.02B $0.00B 10.69
2013-09-30 $0.02B $0.00B 9.00
2013-06-30 $0.00B $0.00B 0.61
2013-03-31 $0.00B $0.00B 0.00
2012-12-31 $0.00B $0.00B 0.00
2012-09-30 $0.00B $0.00B 0.00
2012-06-30 $0.00B $0.00B 0.00
2011-12-31 $0.00B $0.00B 2.73
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.054B $0.000B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.676B 8.40
Teva Pharmaceutical Industries (TEVA) Israel $17.694B 6.11
Mylan (MYL) United Kingdom $16.304B 6.71
Bausch Health Cos (BHC) Canada $8.412B 5.98
Dr Reddy's Laboratories (RDY) India $5.939B 23.69
Supernus Pharmaceuticals (SUPN) United States $1.968B 18.64
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.768B 2.95
Amphastar Pharmaceuticals (AMPH) United States $1.134B 123.05
Homology Medicines (FIXX) United States $0.930B 0.00
CymaBay Therapeutics (CBAY) United States $0.593B 0.00
Assembly Biosciences (ASMB) United States $0.541B 0.00
Akorn (AKRX) United States $0.507B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.402B 0.00
Voyager Therapeutics (VYGR) United States $0.355B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.307B 0.00
Sol-Gel Technologies (SLGL) Israel $0.122B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.086B 0.00
Teligent (TLGT) United States $0.077B 0.00
Acasti Pharma (ACST) Canada $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00
China Pharma Holdings (CPHI) China $0.012B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.004B 0.00